Stockscreener 앱 받기
81.68
6.23%
-5.43
시간 외 거래:
82.00
0.32
+0.39%
Blueprint Medicines Corp 주식(BPMC)의 최신 뉴스
Blueprint Medicines stock hits 52-week low at $80.64 - Investing.com
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Bought by Vanguard Group Inc. - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Corebridge Financial Inc. - The AM Reporter
Exclusive: Blueprint Medicines Leadership Takes Center Stage at Major Healthcare Conference - Stock Titan
Is Blueprint Medicines (BPMC) One of the Best Mid Cap Biotech Stocks to Buy? - Insider Monkey
Blueprint Medicines at H.C. Wainwright Conference: Strategic Pipeline Expansion - Investing.com
Blueprint Medicines at H.C. Wainwright Conference: Strategic Pipeline Expansion By Investing.com - Investing.com UK
Blueprint Medicines COO Christina Rossi sells shares worth $216,075 By Investing.com - Investing.com Canada
Blueprint Medicines COO Christina Rossi sells shares worth $216,075 - Investing.com India
Is Blueprint Medicines Corporation (BPMC) a Promising Biotech Stock According to Wall Street Analysts - Yahoo Finance
PNC Financial Services Group Inc. Boosts Stake in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Proficio Capital Partners LLC Makes New $1.01 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines Co. (NASDAQ:BPMC) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
The Analyst Verdict: Blueprint Medicines In The Eyes Of 14 Experts - Benzinga
Blueprint Medicines (BPMC): Among Stocks Insiders Are Selling In March - Insider Monkey
Morgan Stanley sets Blueprint Medicines stock at Equalweight, $100 target - Investing.com
Morgan Stanley sets Blueprint Medicines stock at Equalweight, $100 target By Investing.com - Investing.com UK
Blueprint Medicines’ SWOT analysis: stock poised for growth amid challenges - Investing.com
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Victory Capital Management Inc. - Defense World
Wolfe Research initiates Blueprint Medicines with Outperform rating - Investing.com
Blueprint Medicines (NASDAQ:BPMC) Now Covered by Jefferies Financial Group - Defense World
This Blueprint Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
241,966 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Purchased by Raymond James Financial Inc. - Defense World
Blueprint Medicines initiated with a Buy at Jefferies - TipRanks
Jefferies sets Blueprint Medicines stock Buy rating, $135 target - Investing.com
Jefferies sets Blueprint Medicines stock Buy rating, $135 target By Investing.com - Investing.com Philippines
Blueprint Medicines (NASDAQ:BPMC) Shares Down 1.6% – Here’s Why - Defense World
Blueprint Medicines director Jeffrey Albers sells $658,500 in stock By Investing.com - Investing.com Australia
Steward Partners Investment Advisory LLC Lowers Position in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines director Jeffrey Albers sells $658,500 in stock - Investing.com India
Charles Schwab Investment Management Inc. Purchases 7,165 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines’ SWOT analysis: strong Ayvakit sales drive stock outlook By Investing.com - Investing.com South Africa
Blueprint Medicines’ SWOT analysis: strong Ayvakit sales drive stock outlook - Investing.com
US Bancorp DE Sells 1,988 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines Co. (NASDAQ:BPMC) Stock Holdings Lifted by Bank of New York Mellon Corp - Defense World
Blueprint Medicines (NASDAQ:BPMC) Coverage Initiated at Scotiabank - Defense World
Blueprint Medicines CFO sells shares worth $469,219 By Investing.com - Investing.com South Africa
Proficio Capital Partners LLC Purchases Shares of 11,600 Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Zacks Research Has Positive Outlook for BPMC Q1 Earnings - Defense World
Blueprint Medicines Stock: Executives Sell Shares Amid Growth - sharewise
Blueprint Medicines CMO Hewes L. Becker sells $890k in stock - Investing.com Canada
Blueprint Medicines CEO sells $1.43 million in stock By Investing.com - Investing.com Canada
Blueprint Medicines EVP sells shares worth $467,265 By Investing.com - Investing.com South Africa
Blueprint Medicines CEO sells $1.43 million in stock - Investing.com
Blueprint Medicines EVP sells shares worth $467,265 - Investing.com India
Blueprint Medicines chief commercial officer Lee Philina sells $331,490 in stock - Investing.com
Blueprint Medicines CFO sells shares worth $469,219 - Investing.com
Blueprint Medicines Executives Sell Shares to Cover Tax Obligations - TradingView
10.70%
자본화:
|
볼륨(24시간):